These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

437 related articles for article (PubMed ID: 27007213)

  • 1. Cost-Utility Analysis of Infliximab with Standard Care versus Standard Care Alone for Induction and Maintenance Treatment of Patients with Ulcerative Colitis in Poland.
    Stawowczyk E; Kawalec P; Pilc A
    Pharmacotherapy; 2016 May; 36(5):472-81. PubMed ID: 27007213
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-utility analysis of 1-year treatment with adalimumab/standard care and standard care alone for ulcerative colitis in Poland.
    Stawowczyk E; Kawalec P; Pilc A
    Eur J Clin Pharmacol; 2016 Nov; 72(11):1319-1325. PubMed ID: 27497991
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-Effectiveness Analysis of 1-Year Treatment with Golimumab/Standard Care and Standard Care Alone for Ulcerative Colitis in Poland.
    Stawowczyk E; Kawalec P; Pilc A
    PLoS One; 2016; 11(8):e0160444. PubMed ID: 27494322
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-Effectiveness Analysis of Tofacitinib Compared with Biologics in Biologic-Naïve Patients with Moderate-to-Severe Ulcerative Colitis in Japan.
    Kobayashi T; Hoshi M; Yuasa A; Arai S; Ikeda M; Matsuda H; Kim SW; Hibi T
    Pharmacoeconomics; 2023 May; 41(5):589-604. PubMed ID: 36884164
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness analysis of infliximab, adalimumab, golimumab and vedolizumab for moderate to severe ulcerative colitis in Spain.
    Trigo-Vicente C; Gimeno-Ballester V; Montoiro-Allué R; López-Del Val A
    Expert Rev Pharmacoecon Outcomes Res; 2018 Jun; 18(3):321-329. PubMed ID: 29192530
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Model-Based Economic Evaluation of Biologic and Non-Biologic Options for the Treatment of Adults with Moderately-to-Severely Active Ulcerative Colitis after the Failure of Conventional Therapy.
    Tappenden P; Ren S; Archer R; Harvey R; James MM; Basarir H; Stevens J; Lobo A; Hoque S
    Pharmacoeconomics; 2016 Oct; 34(10):1023-38. PubMed ID: 27125898
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness analysis of adjunct VSL#3 therapy versus standard medical therapy in pediatric ulcerative colitis.
    Park KT; Perez F; Tsai R; Honkanen A; Bass D; Garber A
    J Pediatr Gastroenterol Nutr; 2011 Nov; 53(5):489-96. PubMed ID: 21694634
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Direct healthcare costs and cost-effectiveness of acute coronary syndrome secondary prevention with ticagrelor compared to clopidogrel: economic evaluation from the public payer's perspective in Poland based on the PLATO trial results.
    Pawęska J; Macioch T; Perkowski P; Budaj A; Niewada M
    Kardiol Pol; 2014; 72(9):823-30. PubMed ID: 24846362
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of vedolizumab compared with infliximab, adalimumab, and golimumab in patients with ulcerative colitis in the United Kingdom.
    Wilson MR; Bergman A; Chevrou-Severac H; Selby R; Smyth M; Kerrigan MC
    Eur J Health Econ; 2018 Mar; 19(2):229-240. PubMed ID: 28271250
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost per remission and cost per response with infliximab, adalimumab, and golimumab for the treatment of moderately-to-severely active ulcerative colitis.
    Toor K; Druyts E; Jansen JP; Thorlund K
    J Med Econ; 2015 Jun; 18(6):437-46. PubMed ID: 25629655
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimal treatment sequence for targeted immune modulators for the treatment of moderate to severe ulcerative colitis.
    Bloudek LM; Pandey R; Fazioli K; Ollendorf DA; Carlson JJ
    J Manag Care Spec Pharm; 2021 Aug; 27(8):1046-1055. PubMed ID: 34337994
    [No Abstract]   [Full Text] [Related]  

  • 12. Cost-effectiveness analysis of infliximab, adalimumab, golimumab, vedolizumab and tofacitinib for moderate to severe ulcerative colitis in Spain.
    Trigo-Vicente C; Gimeno-Ballester V; López-Del Val A
    Eur J Hosp Pharm; 2020 Nov; 27(6):355-360. PubMed ID: 33097619
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of tofacitinib compared with infliximab, adalimumab, golimumab, vedolizumab and ustekinumab for the treatment of moderate to severe ulcerative colitis in Germany.
    Sardesai A; Dignass A; Quon P; Milev S; Cappelleri JC; Kisser A; Modesto I; Sharma PP
    J Med Econ; 2021; 24(1):279-290. PubMed ID: 33502905
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of golimumab for the treatment of patients with moderate-to-severe ulcerative colitis in Quebec using a patient level state transition microsimulation.
    Stern S; Ward AJ; Saint-Laurent Thibault C; Camacho F; Rahme E; Naessens D; Aumais G; Bernard EJ; Bourdages R; Cohen A; Pare P; Dyrda P
    J Med Econ; 2018 Jan; 21(1):27-37. PubMed ID: 28830258
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of 5-aminosalicylic acid therapy for maintenance of remission in ulcerative colitis.
    Yen EF; Kane SV; Ladabaum U
    Am J Gastroenterol; 2008 Dec; 103(12):3094-105. PubMed ID: 18775007
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of infliximab for the treatment of acute exacerbations of ulcerative colitis.
    Punekar YS; Hawkins N
    Eur J Health Econ; 2010 Feb; 11(1):67-76. PubMed ID: 19844750
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-life treatment paradigms show infliximab is cost-effective for management of ulcerative colitis.
    Ung V; Thanh NX; Wong K; Kroeker KI; Lee T; Wang H; Ohinmaa A; Jacobs P; Fedorak RN
    Clin Gastroenterol Hepatol; 2014 Nov; 12(11):1871-8.e8. PubMed ID: 24674943
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Canadian cost-utility analysis of initiation and maintenance treatment with anti-TNF-α drugs for refractory Crohn's disease.
    Blackhouse G; Assasi N; Xie F; Marshall J; Irvine EJ; Gaebel K; Campbell K; Hopkins R; O'Reilly D; Tarride JE; Goeree R
    J Crohns Colitis; 2012 Feb; 6(1):77-85. PubMed ID: 22261531
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A model of the long-term cost effectiveness of scheduled maintenance treatment with infliximab for moderate-to-severe ulcerative colitis.
    Tsai HH; Punekar YS; Morris J; Fortun P
    Aliment Pharmacol Ther; 2008 Nov; 28(10):1230-9. PubMed ID: 18729845
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Infliximab, adalimumab, golimumab, vedolizumab and tofacitinib in moderate to severe ulcerative colitis: comparative cost-effectiveness study in Poland.
    Petryszyn P; Ekk-Cierniakowski P; Zurakowski G
    Therap Adv Gastroenterol; 2020; 13():1756284820941179. PubMed ID: 32922513
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.